迈科康生物 迈科康生物

CN

We focus on the R&D and production of innovative vaccines and new adjuvants.

about

mAXVAX

We focus on the R&D and production of innovative vaccines and new adjuvants.

Maxvax Biotechnology was founded by Dr. Dexiang Chen in 2016 in China's south-western city of Chengdu. We are a global biopharmaceutical enterprise dedicated to the research, development, production and commercialization of innovative vaccines and new adjuvants.
More

Technology

& production

We provide customers with high-quality, safe
and innovative products.

Technology Platform

Maxvax has pioneered three technological platforms: recombinant protein, adjuvants, and mRNA, aimed at treating infectious diseases, cancer, and allergies.

Learn more

Technology
Platform

+

Pipeline Introduction

Utilizing our technology platforms, we have developed a diverse pipeline of prophylactic and therapeutic vaccines to combat global health burdens.

Learn more

Pipeline
Introduction

+

Production Capability

We have constructed over 200,000 sq ft of state-of-the-art R&D and manufacturing facilities to support our pipeline, enabling us to handle product development all the way to industrial scale manufacturing, all in-house.

Learn more...

Production
Capability

+

news

center

Maxvax Newsletters

  • 022023.11

    Maxvax Receives Funding for a Pioneering Therapeutic HPV Vaccine Targeted for Global Public Health

    Maxvax has received funding from the Bill & Melinda Gates Foundation to support the development of a low-cost HPV therapeutic vaccine candidate, aligning with global efforts to address the challenges posed by HPV infection that can lead to cervical cancer.

    more >

  • 162023.09

    Maxvax founder and CEO Dr. Chen gave speech at GVIRF

    On September 13th, 2023, the Global Health Vaccine Adjuvant Webinar, which was hosted by Global Vaccine and Immunization Research Forum (GVIRF), was successfully held. Maxvax was the only innovative vaccine company in China that was invited to attend the virtual seminar. On the meeting, Maxvax’s founder and CEO Dr. Dexiang Chen gave a presentation on Enhancing Public Health Capacity: Strengthening the Global Availability, Accessibility, and Affordability of Adjuvants and Formulations, and took part in the keynote discussion.

    more >

  • 072023.05

    Milestone | Kick-off Meeting for Phase II Clinical Study of Recombinant Herpes Zoster Vaccine Successfully Held

    On May 6, 2023, the kick-off meeting for the Phase II clinical study of Maxvax’s Recombinant Herpes Zoster Vaccine (CHO Cell) Biotechnology was successfully held in China’s northern province of Henan, and the enrollment was scheduled to be initiated on the next day.

    more >
See more

contact

mAXVAX

We are here if you have any questions and needs.

  • Contact Us

  • Opportunities

  • Branches